April 30, 2018: FemPulse Completes Private Placement Financing
FemPulse Corporation announced completion in the first quarter of 2018 of a private financing round, which will enable acceleration of the development of its novel and proprietary bioelectronic therapy for overactive bladder (OAB) in females. Proceeds will be used for technical and clinical evidence development in preparation for commercialization of the therapy in the US […]
April 4, 2018: Clinical Results to be Presented at IUGA Annual Meeting
The results of the FemPulse clinical study will be presented at the International Urogynecological Association (IUGA) annual meeting to be held in Vienna, Austria on June 27 – 30, 2018. The invitation provides an opportunity to share the exciting potential of FemPulse with a premier global audience in the field of urogynecology. Dr. Suzette Sutherland, […]
